The study aimed to identify distinct subgroups of medulloblastoma based on genomic and transcriptomic data. The researchers analyzed gene expression profiles and DNA copy number aberrations in 103 primary medulloblastomas and used bioinformatic tools to classify the tumors into four distinct molecular variants: WNT, SHH, group C, and group D. Immunohistochemistry for subgroup-specific signature genes was used to validate the subgroups in 294 non-overlapping medulloblastomas. The four subgroups showed significant differences in demographics, histology, metastatic status, and genetic abnormalities. Group C tumors, characterized by high MYC expression, had a significantly worse prognosis compared to other subgroups. The study concluded that medulloblastomas can be reliably classified into these four subgroups, which have distinct clinical outcomes and genetic profiles. This classification will aid in patient stratification and the development of targeted therapies.The study aimed to identify distinct subgroups of medulloblastoma based on genomic and transcriptomic data. The researchers analyzed gene expression profiles and DNA copy number aberrations in 103 primary medulloblastomas and used bioinformatic tools to classify the tumors into four distinct molecular variants: WNT, SHH, group C, and group D. Immunohistochemistry for subgroup-specific signature genes was used to validate the subgroups in 294 non-overlapping medulloblastomas. The four subgroups showed significant differences in demographics, histology, metastatic status, and genetic abnormalities. Group C tumors, characterized by high MYC expression, had a significantly worse prognosis compared to other subgroups. The study concluded that medulloblastomas can be reliably classified into these four subgroups, which have distinct clinical outcomes and genetic profiles. This classification will aid in patient stratification and the development of targeted therapies.